CELL INTELLIGENCE · 肿瘤细胞治疗研究

非小细胞肺癌代谢重编程的治疗策略

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.

非小细胞肺癌的 CAR-T 治疗：临床前景、潜力与心脏毒性管理策略

CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.

EGFR CAR NK 与 CAR-T 细胞对 EGFR 抑制剂耐药 NSCLC 及药物耐受持留细胞的活性

The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.

靶向 EGFR 的细胞疗法，尤其是 EGFR CAR NK 细胞，在体外和体内对 EGFR 突变型 DTPC 和 DRC 显示出活性，与 EGFR TKI 或 TGF- 通路阻断联合时活性增强。

通过靶向 TROP2 的 CAR-T 细胞疗法清除 EGFR 突变非小细胞肺癌中的耐药持留细胞

Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.

验证 CCL20 驱动的分泌 PD-1 阻断剂的 CAR-γδ T 细胞及其向实体瘤增强的迁移能力

Validation of CCL20-driven CAR-γδ T secreting PD-1 blockade with enhanced trafficking into solid tumor.

EGFR TKIs 通过 PI3K/AKT/SP1/C1GALT1 通路抑制 MUC1 糖基化以增强 TnMUC1 CAR-T 在 EGFR 突变非小细胞肺癌中的疗效

EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC.

肺癌治疗新策略：免疫治疗、精准医学与人工智能改善预后的深度分析

Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence t

CAR-T 细胞治疗非小细胞肺癌的进展

Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.

勘误：基于配体、piggyBac 工程化的靶向 EGFR 的 CAR-T 细胞对非小细胞肺癌安全有效

Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers.

基于配体、piggyBac 工程化的靶向 EGFR 的 CAR-T 细胞对非小细胞肺癌安全有效

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers.